...
首页> 外文期刊>Journal of Clinical and Basic Cardiology (Print): an independent international scientific journal >Prognostic Significance of Short-Period Heart Rate Variability in Patients with Acute Myocardial Infarction in the Era of Modern Infarction Therapy
【24h】

Prognostic Significance of Short-Period Heart Rate Variability in Patients with Acute Myocardial Infarction in the Era of Modern Infarction Therapy

机译:现代梗死治疗时代急性心肌梗死患者短期心率变异性的预后意义

获取原文
           

摘要

We aimed to prospectively assess the prognostic value of decreased heart rate variability (HRV) in the era of modern infarction therapy with high rates of reperfusion therapy and beta-blocker use. Short-term HRV in the frequency domain was measured in 129 consecutive patients (age < 74 years) 5 to 8 days after an acute myocardial infarction (AMI). HRV-parameters were subdivided according to predefined cut-points. Patients were followed for a mean of 38 months (range 1–47) for arrhythmic events, cardiac and noncardiac death, and recurrent nonfatal myocardial infarction or angina requiring hospitalization. The majority of patients received acute revascularization (60 %), and most were treated with b-blockers (89 %) and aspirin (95 %). Accordingly, the rate of endpoints were relatively low (9 deaths or malignant arrhythmias; 14 nonfatal reinfarctions or angina). Patients with the combined endpoint death, malignant arrhythmia or nonfatal cardiac event had significantly lower mean and median low frequency (LF) and total frequency power. Accordingly, the relative risk of reaching any endpoint of those with low LF-power was 2.3 times (Confidence Interval 1.03; 5.3) higher compared to those with normal HRV. This association persisted in the multivariate model controlling for age, ejection fraction and treatment. In conclusion, these data show that in the era of modern infarction therapy with high rates of acute reperfusion therapy and optimized medical therapy, an easily applicable test for autonomic dysfunction, ie short-term HRV-measurement, remains a significant predictor of the patients’ risk for future adverse events.
机译:我们的目的是前瞻性评估在具有高再灌注治疗率和使用β受体阻滞剂的现代梗塞治疗时代,降低心率变异性(HRV)的预后价值。在急性心肌梗死(AMI)后5至8天连续129位患者(年龄<74岁)中测量了频域的短期HRV。 HRV参数根据预定义的切点进行细分。对患者进行平均38个月(1-47个月)的心律失常事件,心源性和非心源性死亡以及复发性非致命性心肌梗塞或需要住院治疗的心绞痛的随访。大多数患者接受了急性血运重建(60%),大多数患者接受了b受体阻滞剂(89%)和阿司匹林(95%)的治疗。因此,终点发生率相对较低(9例死亡或恶性心律失常; 14例非致命性再梗塞或心绞痛)。合并终点死亡,恶性心律不齐或非致命性心脏事件的患者的平均和中位数低频(LF)和总频率功率显着降低。因此,与低心率功率者相比,达到低心率功率者终点的相对风险高出2.3倍(置信区间1.03; 5.3)。这种关联持续存在于控制年龄,射血分数和治疗的多变量模型中。总之,这些数据表明,在具有高急性再灌注治疗率和优化药物治疗率的现代梗塞治疗时代,一种易于应用的自主神经功能障碍测试(即短期HRV测量)仍然是患者病情严重的重要指标。未来不良事件的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号